Search

Your search keyword '"Snyder, Heather"' showing total 589 results
Start Over Author "Snyder, Heather"
589 results on '"Snyder, Heather"'

58. Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective.

Author

Elahi, Fanny, Elahi, Fanny, Alladi, Suvarna, Black, Sandra, Claassen, Jurgen, DeCarli, Charles, Hughes, Timothy, Moonen, Justine, Pajewski, Nicholas, Price, Brittani, Satizabal, Claudia, Shaaban, C, Silva, Nárlon, Snyder, Heather, Sveikata, Lukas, Williamson, Jeff, Wolters, Frank, Hainsworth, Atticus, Elahi, Fanny, Elahi, Fanny, Alladi, Suvarna, Black, Sandra, Claassen, Jurgen, DeCarli, Charles, Hughes, Timothy, Moonen, Justine, Pajewski, Nicholas, Price, Brittani, Satizabal, Claudia, Shaaban, C, Silva, Nárlon, Snyder, Heather, Sveikata, Lukas, Williamson, Jeff, Wolters, Frank, and Hainsworth, Atticus

Abstract

A large interventional trial, the Systolic Blood Pressure Intervention Trial sub-study termed Memory and Cognition in Decreased Hypertension (SPRINT-MIND), found reduced risk of cognitive impairment in older adults with intensive, relative to standard, blood-pressure-lowering targets (systolic BP < 120 vs. <140 mm Hg). In this perspective, we discuss key questions and make recommendations for clinical practice and for clinical trials, following SPRINT-MIND. Future trials should embody cognitive endpoints appropriate to the participant group, ideally with adaptive designs that ensure robust answers for cognitive and cardiovascular endpoints. Reliable data from diverse populations, including the oldest-old (age > 80 years), will maximize external validity and global implementation of trial findings. New biomarkers will improve phenotyping to stratify patients to optimal treatments. Currently no antihypertensive drug class stands out for dementia risk reduction. Multi-domain interventions, incorporating lifestyle change (exercise, diet) alongside medications, may maximize global impact. Given the low cost and wide availability of antihypertensive drugs, intensive BP reduction may be a cost-effective means to reduce dementia risk in diverse, aging populations worldwide.

Published
2023

59. Clinical trials in vascular cognitive impairment following SPRINT-MIND:An international perspective

Author

Elahi, Fanny M., Alladi, Suvarna, Black, Sandra E., Claassen, Jurgen A.H.R., DeCarli, Charles, Hughes, Timothy M., Moonen, Justine, Pajewski, Nicholas M., Price, Brittani R., Satizabal, Claudia, Shaaban, C. Elizabeth, Silva, Nárlon C.B.S., Snyder, Heather M., Sveikata, Lukas, Williamson, Jeff D., Wolters, Frank J., Hainsworth, Atticus H., Elahi, Fanny M., Alladi, Suvarna, Black, Sandra E., Claassen, Jurgen A.H.R., DeCarli, Charles, Hughes, Timothy M., Moonen, Justine, Pajewski, Nicholas M., Price, Brittani R., Satizabal, Claudia, Shaaban, C. Elizabeth, Silva, Nárlon C.B.S., Snyder, Heather M., Sveikata, Lukas, Williamson, Jeff D., Wolters, Frank J., and Hainsworth, Atticus H.

Abstract

A large interventional trial, the Systolic Blood Pressure Intervention Trial sub-study termed Memory and Cognition in Decreased Hypertension (SPRINT-MIND), found reduced risk of cognitive impairment in older adults with intensive, relative to standard, blood-pressure-lowering targets (systolic BP < 120 vs. <140 mm Hg). In this perspective, we discuss key questions and make recommendations for clinical practice and for clinical trials, following SPRINT-MIND. Future trials should embody cognitive endpoints appropriate to the participant group, ideally with adaptive designs that ensure robust answers for cognitive and cardiovascular endpoints. Reliable data from diverse populations, including the oldest-old (age > 80 years), will maximize external validity and global implementation of trial findings. New biomarkers will improve phenotyping to stratify patients to optimal treatments. Currently no antihypertensive drug class stands out for dementia risk reduction. Multi-domain interventions, incorporating lifestyle change (exercise, diet) alongside medications, may maximize global impact. Given the low cost and wide availability of antihypertensive drugs, intensive BP reduction may be a cost-effective means to reduce dementia risk in diverse, aging populations worldwide.

Published
2023

60. European Working Group on SARS-CoV-2: Current Understanding, Unknowns, and Recommendations on the Neurological Complications of COVID-19

Author

Cardiovasculaire Epi Team 5, Brain, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Crook, Harry, Ramirez, Alfredo, Hosseini, Akram, Vavougyios, Georgios, Lehmann, Clara, Bruchfeld, Judith, Schneider, Anja, D'avossa, Giovanni, Lo Re, Vincenzina, Salmoiraghi, Alberto, Mukaetova-Ladinska, Elizabeta, Katshu, Mohammad, Boneschi, Filippo M., Håkansson, Krister, Geerlings, Mirjam, Pracht, Elisabeth, Ruiz, Agustín, Jansen, Jacobus F.A., Snyder, Heather, Kivipelto, Miia, Edison, Paul, Cardiovasculaire Epi Team 5, Brain, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Crook, Harry, Ramirez, Alfredo, Hosseini, Akram, Vavougyios, Georgios, Lehmann, Clara, Bruchfeld, Judith, Schneider, Anja, D'avossa, Giovanni, Lo Re, Vincenzina, Salmoiraghi, Alberto, Mukaetova-Ladinska, Elizabeta, Katshu, Mohammad, Boneschi, Filippo M., Håkansson, Krister, Geerlings, Mirjam, Pracht, Elisabeth, Ruiz, Agustín, Jansen, Jacobus F.A., Snyder, Heather, Kivipelto, Miia, and Edison, Paul

Published
2023

61. European Working Group on SARS-CoV-2: Current Understanding, Unknowns, and Recommendations on the Neurological Complications of COVID-19

Author

Crook, Harry, Ramirez, Alfredo, Hosseini, Akram, Vavougyios, Georgios, Lehmann, Clara, Bruchfeld, Judith, Schneider, Anja, D'Avossa, Giovanni, Lo Re, Vincenzina, Salmoiraghi, Alberto, Mukaetova-Ladinska, Elizabeta, Katshu, Mohammad, Boneschi, Filippo M., Hakansson, Krister, Geerlings, Mirjam, Pracht, Elisabeth, Ruiz, Agustin, Jansen, Jacobus F. A., Snyder, Heather, Kivipelto, Miia, Edison, Paul, Crook, Harry, Ramirez, Alfredo, Hosseini, Akram, Vavougyios, Georgios, Lehmann, Clara, Bruchfeld, Judith, Schneider, Anja, D'Avossa, Giovanni, Lo Re, Vincenzina, Salmoiraghi, Alberto, Mukaetova-Ladinska, Elizabeta, Katshu, Mohammad, Boneschi, Filippo M., Hakansson, Krister, Geerlings, Mirjam, Pracht, Elisabeth, Ruiz, Agustin, Jansen, Jacobus F. A., Snyder, Heather, Kivipelto, Miia, and Edison, Paul

Abstract

Background: The emergence of COVID-19 was rapidly followed by infection and the deaths of millions of people across the globe. With much of the research and scientific advancement rightly focused on reducing the burden of severe and critical acute COVID-19 infection, the long-term effects endured by those who survived the acute infection has been previously overlooked. Now, an appreciation for the post-COVID-19 condition, including its neurological manifestations, is growing, although there remain many unknowns regarding the etiology and risk factors of the condition, as well as how to effectively diagnose and treat it.Methods: Here, drawing upon the experiences and expertise of the clinicians and academics of the European working group on COVID-19, we have reviewed the current literature to provide a comprehensive overview of the neurological sequalae of the post-COVID-19 condition.Results: In this review, we provide a summary of the neurological symptoms associated with the post-COVID-19 condition, before discussing the possible mechanisms which may underly and manifest these symptoms. Following this, we explore the risk factors for developing neurological symptoms as a result of COVID-19 and the post-COVID-19 condition, as well as how COVID-19 infection may itself be a risk factor for the development of neurological disease in the future. Lastly, we evaluate how the post-COVID condition could be accurately diagnosed and effectively treated, including examples of the current guidelines, clinical outcomes, and tools that have been developed to aid in this process, as well as addressing the protection provided by COVID-19 vaccines against the post-COVID-19 condition.Conclusions: Overall, this review provides a comprehensive overview of the neurological sequalae of the post-COVID-19 condition. Impact statementWith our understanding of the neurological complications of the post-COVID-19 condition currently lacking sufficient depth, this review aimed at highlighting th

Published
2023

62. Clearance of interstitial fluid (ISF) and CSF (CLIC) group‐part of Vascular Professional Interest Area (PIA), updates in 2022‐2023. Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina...

Author

Kelly, Louise, Brown, Christopher, Michalik, Daniel, Hawkes, Cheryl A., Aldea, Roxana, Agarwal, Nivedita, Salib, Rami, Alzetani, Aiman, Ethell, Douglas W, Counts, Scott E., de Leon, Mony, Fossati, Silvia, Koronyo‐Hamaoui, Maya, Piazza, Fabrizio, Rich, Steven A., Wolters, Frank J., Snyder, Heather, Ismail, Ozama, Elahi, Fanny, and Proulx, Steven T.

Abstract

This editorial summarizes advances from the Clearance of Interstitial Fluid and Cerebrospinal Fluid (CLIC) group, within the Vascular Professional Interest Area (PIA) of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART). The overarching objectives of the CLIC group are to: (1) understand the age‐related physiology changes that underlie impaired clearance of interstitial fluid (ISF) and cerebrospinal fluid (CSF) (CLIC); (2) understand the cellular and molecular mechanisms underlying intramural periarterial drainage (IPAD) in the brain; (3) establish novel diagnostic tests for Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), retinal amyloid vasculopathy, amyloid‐related imaging abnormalities (ARIA) of spontaneous and iatrogenic CAA‐related inflammation (CAA‐ri), and vasomotion; and (4) establish novel therapies that facilitate IPAD to eliminate amyloid β (Aβ) from the aging brain and retina, to prevent or reduce AD and CAA pathology and ARIA side events associated with AD immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

63. Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER).

Author

Baker, Laura D., Snyder, Heather M., Espeland, Mark A., Whitmer, Rachel A., Kivipelto, Miia, Woolard, Nancy, Katula, Jeffrey, Papp, Kathryn V., Ventrelle, Jennifer, Graef, Sarah, Hill, Marcus A., Rushing, Scott, Spell, Julia, Lovato, Laura, Felton, Deborah, Williams, Benjamin J., Ghadimi Nouran, Mina, Raman, Rema, Ngandu, Tiia, and Solomon, Alina

Abstract

INTRODUCTION: The U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER) is conducted to confirm and expand the results of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) in Americans. METHODS: U.S. POINTER was planned as a 2‐year randomized controlled trial of two lifestyle interventions in 2000 older adults at risk for dementia due to well‐established factors. The primary outcome is a global cognition composite that permits harmonization with FINGER. RESULTS: U.S. POINTER is centrally coordinated and conducted at five clinical sites (ClinicalTrials.gov: NCT03688126). Outcomes assessments are completed at baseline and every 6 months. Both interventions focus on exercise, diet, cognitive/social stimulation, and cardiovascular health, but differ in intensity and accountability. The study partners with a worldwide network of similar trials for harmonization of methods and data sharing. DISCUSSION: U.S. POINTER is testing a potentially sustainable intervention to support brain health and Alzheimer's prevention for Americans. Impact is strengthened by the targeted participant diversity and expanded scientific scope through ancillary studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

64. Latin American Initiative for Lifestyle Intervention to Prevent Cognitive Decline (LatAm‐FINGERS): Study design and harmonization

Author

Crivelli, Lucia, primary, Calandri, Ismael Luis, additional, Suemoto, Claudia Kimie, additional, Salinas, Rosa María, additional, Velilla, Lina Marcela, additional, Yassuda, Mônica Sanches, additional, Caramelli, Paulo, additional, Lopera, Francisco, additional, Nitrini, Ricardo, additional, Sevlever, Gustavo Emilio, additional, Sosa, Ana Luisa, additional, Acosta, Daisy, additional, Baietti, Ana María Charamelo, additional, Cusicanqui, María Isabel, additional, Custodio, Nilton, additional, De Simone, Sergio Dansilio, additional, Derio, Carolina Delgado, additional, Duque‐Peñailillo, Lissette, additional, Duran, Juan Carlos, additional, Jiménez‐Velázquez, Ivonne Z., additional, Leon‐Salas, Jorge Mario, additional, Bergamo, Yanina, additional, Clarens, María Florencia, additional, Damian, Andrés, additional, Demey, Ignacio, additional, Helou, María Belén, additional, Márquez, Carlos, additional, Martin, María Eugenia, additional, Martin, Maria da Graça Morais, additional, Querze, Diego, additional, Surace, Ezequiel Ignacio, additional, Acosta‐Egea, Sabrina, additional, Aguirre–Salvador, Esteban, additional, de Souza, Leonardo Cruz, additional, Cançado, Gustavo Henrique da Cunha Peixoto, additional, Brucki, Sonia Maria Dozzi, additional, Friedlaender, Clarisse Vasconcelos, additional, Gomes, Karina Braga, additional, Gutierrez, Myriam, additional, Ríos, Carlos Laforcada, additional, Galindo, Joyce Graciela Martinez, additional, Montesinos, Rosa, additional, Nuñez‐Herrera, Alberto, additional, Ospina‐Henao, Sebastián, additional, Rodríguez, Guillermina, additional, Masson, Victoria Ruiz, additional, Sánchez, Mónica, additional, Schenk, Christian E., additional, Soto, Ligia, additional, Barbosa, Maira Tonidandel, additional, Tosatti, Jéssica Abdo Gonçalves, additional, Vicuña, Yosselin, additional, Espeland, Mark, additional, Hakansson, Krister, additional, Kivipelto, Miia, additional, Baker, Laura, additional, Snyder, Heather, additional, Carrillo, María, additional, and Allegri, Ricardo Francisco, additional

Published
2023
Full Text
View/download PDF

65. European Working Group on SARS-CoV-2: Current Understanding, Unknowns, and Recommendations on the Neurological Complications of COVID-19

Author

Crook, Harry, primary, Ramirez, Alfredo, additional, Hosseini, Akram, additional, Vavougyios, Georgios, additional, Lehmann, Clara, additional, Bruchfeld, Judith, additional, Schneider, Anja, additional, D'Avossa, Giovanni, additional, Lo Re, Vincenzina, additional, Salmoiraghi, Alberto, additional, Mukaetova-Ladinska, Elizabeta, additional, Katshu, Mohammad, additional, Boneschi, Filippo M., additional, Håkansson, Krister, additional, Geerlings, Mirjam, additional, Pracht, Elisabeth, additional, Ruiz, Agustín, additional, Jansen, Jacobus F.A., additional, Snyder, Heather, additional, Kivipelto, Miia, additional, and Edison, Paul, additional

Published
2023
Full Text
View/download PDF

68. Contributors for Volume 1

Author

Abbas, Zaigham, Abdullah, Khalid, Acharya, Subrat Kumar, Aghayeva, Gulnara, Ahmad, Jawad, Akbar, Sheikh Mohammad Fazle, Arora, Anil, Asp, Patrik, Bansal, Meena B., Bedewy, Essam, Bernardi, Mauro, Bernstein, David, Boregowda, Umesha, Caldwell, Stephen H., Calmet, Fernando, Carlini, Lauren E., Crawford, James M., Dhiman, Radha K., Dhiman, Siddhant, Dutta, Usha, Gallagher, Julie, Gish, Robert G., Grewal, Priya, Guha, Chandan, Gupta, Pankaj, Gutierrez, Julio A., Jothimani, Dinesh, Kar, Premashis, Karna, Rahul, Khanna, Rohit, Koneru, Gopala, Kothadia, Jiten P., Latt, Nyan L., Levy, Cynthia, Mamun-Al-Mahtab, Maliakkal, Benedict J., Manjunath, Srividya, Mann, Rupinder, Martin, Paul, Miller, Jennifer B., Omiwade, Oluwaposi, Ormeci, Necati, Prevallet, Alex, Rattan, Puru, Rizzetto, Mario, Roy, Akash, Roy-Chowdhury, Jayanta, Roy-Chowdhury, Namita, Satiya, Jinendra, Shah, Vijay H., Sharma, Praveen, Sheflin-Findling, Shari, Siddiqui, Mohammad, Snyder, Heather, Syed, Taseen, Trivella, Juan, Tseng, Michael, Turcanu, Adela, Udompap, Prowpanga, Umukoro, Emuejevuoke, Wakil, Ali, Wentworth, Brian J., Wong, Robert J., Yadav, Amit, and Zaccherini, Giacomo

Published
2025
Full Text
View/download PDF

69. The association of cardiovascular risk factors and depressive symptoms on cognitive function in the U.S. POINTER study.

Author

Thro, Amber A, Garcia, Katelyn R, Krueger, Kristin R, Howard, Marjorie, Snyder, Heather M, Baker, Laura D, and Papp, Kathryn V

Abstract

Background: Cardiovascular risk factors and depressive symptoms have both been independently shown to be negatively associated with cognitive function. However, the nature of the influence of comorbid depressive symptoms and cardiovascular risk on cognitive function is unclear, and there have been inconsistent findings as to which cognitive domains may be most associated with this relationship. Method: U.S. POINTER is a randomized controlled trial of two multidomain lifestyle interventions. We examined the baseline relationship between cardiovascular risk, depressive symptoms, and cognitive function in 2103 U.S. POINTER participants (mean age = 68.19±5.16y). The Framingham Risk Score (FRS) using lipids was used to calculate the 10‐year risk of developing cardiovascular disease, and depressive symptoms were assessed using the 15‐item Geriatric Depression Scale (GDS). Cognitive function was measured using composite scores (global, episodic memory, executive function, and processing speed) derived from the U.S. POINTER modified Neuropsychological Test Battery. After computing correlations, generalized linear regression models were used to determine the presence of an interaction between GDS (using a median split of 0‐1 and 2+) and FRS for each cognitive composite while controlling for demographic variables. Result: Higher GDS was significantly associated with lower global cognition (r = ‐0.04, p = 0.04) and slower processing speed (r = ‐0.06, p = 0.01) but not episodic memory (r = ‐0.03, p = 0.17) or executive function (r = ‐0.02, p = 0.37). FRS was negatively associated with global cognition (r = ‐0.25, p<0.01), episodic memory (r = ‐0.27, p<0.01), executive function (r = ‐0.13, p<0.01), and processing speed (r = ‐0.20, p<0.01). Regression models identified the presence of an interaction between FRS and GDS with global cognition (p<0.01). Specifically, participants with lower GDS scores (0‐1) had higher global cognition at lower levels of FRS than those with higher GDS scores (2+), but as FRS approached 16%, participants with lower GDS scores had lower global cognition than those with higher GDS scores. The presence of an interaction between FRS and GDS was also found with the executive function (p<0.01) and processing speed (p = 0.04) composites, but not with the episodic memory (p = 0.12) composite. Conclusion: In U.S. POINTER participants at baseline, the effect of cardiovascular risk on global cognition, executive function, and processing speed may vary depending on the presence and severity of depressive symptoms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

71. Choice of Inversion Time for Arterial Spin Labeling MRI in the U.S. POINTER Lifestyle Intervention Trial

Author

Jung, Youngkyoo, primary, Hong, Sarah Y., additional, Kim, Donghoon, additional, Vemuri, Prashanthi, additional, Borowski, Bret J., additional, Jack, Clifford R., additional, Koeppe, Robert A., additional, Lockhart, Samuel N., additional, Harrison, Theresa M., additional, Gordineer, Leslie, additional, Woolard, Nancy, additional, Espeland, Mark A., additional, Harvey, Danielle J., additional, Lovato, Laura, additional, Toga, Arthur W., additional, Masdeu, Joseph C., additional, Oh, Hwamee, additional, Gitelman, Darren R., additional, Aggarwal, Neelum T., additional, Carrillo, Maria C., additional, Snyder, Heather M., additional, Whitmer, Rachel A., additional, Baker, Laura D., additional, DeCarli, Charles S., additional, and Landau, Susan M., additional

Published
2022
Full Text
View/download PDF

72. The Institute on Methods and Protocols for Advancement of Clinical Trials for ADRD (IMPACT‐AD): An update after two years of conduct.

Author

Grill, Joshua, primary, Berkness, Tyler, additional, Carrillo, Maria C., additional, Snyder, Heather M., additional, Aisen, Paul, additional, Sperling, Reisa A., additional, Petersen, Ronald C., additional, Aggarwal, Neelum T., additional, Bell, Karen L., additional, Burns, Jeffrey M., additional, Donohue, Michael C., additional, Dodge, Hiroko H, additional, Espeland, Mark A., additional, Gillen, Daniel L., additional, Geldmacher, David S., additional, Heidebrink, Judith L, additional, Jicha, Gregory A, additional, Olichney, John M., additional, Rafii, Michael S, additional, Rentz, Dorene M., additional, Salloway, Stephen P., additional, Sethuraman, Gopalan, additional, Smith, Amanda G, additional, and Raman, Rema, additional

Published
2022
Full Text
View/download PDF

73. ALZ‐NET: Using Real World Evidence to Inform the Future of Alzheimer’s Treatment and Care

Author

Rabinovici, Gil D., primary, Rafii, Michael S, additional, Apgar, Charles, additional, An, Na, additional, Barakos, Jerome, additional, Brangman, Sharon A, additional, Daffner, Kirk R, additional, Edelmayer, Rebecca M., additional, Gatsonis, Constantine, additional, Hakim, Rosemarie, additional, Hanna, Lucy, additional, Jicha, Gregory A, additional, Jordan, John, additional, Lingler, Jennifer H, additional, Lopez, Oscar L., additional, March, Andrew, additional, Porsteinsson, Anton P., additional, Possin, Katherine L, additional, Romero, Klaus, additional, Salloway, Stephen P., additional, Sano, Mary, additional, Sivakumaran, Sudhir, additional, Snyder, Heather M., additional, Stebbins, Patricia, additional, Vukmir, Rade B, additional, Whitlow, Christopher T., additional, and Carrillo, Maria C., additional

Published
2022
Full Text
View/download PDF

74. Using 7T MRI to Evaluate COVID‐19 and Brain

Author

Hosseini, Akram A., primary, Bowtell, Richard, additional, Mougin, Olivier, additional, Penny, Gowland, additional, Katshu, Mohammad Zia, additional, Mukaetova‐Ladinska, Elizabeta, additional, Ibrahim, Tamer, additional, Girard, Timothy D., additional, Vahidy, Farhaan S., additional, Jacobs, Heidi I.L., additional, Snyder, Heather M., additional, de Erausquin, Gabriel A., additional, and Seshadri, Sudha, additional

Published
2022
Full Text
View/download PDF

80. A guide for researchers seeking training in retrospective data harmonization for population neuroscience studies of Alzheimer's disease and related dementias

Author

Shaaban, C. Elizabeth, primary, Tudorascu, Dana L., additional, Glymour, M. Maria, additional, Cohen, Ann D., additional, Thurston, Rebecca C., additional, Snyder, Heather M., additional, Hohman, Timothy J., additional, Mukherjee, Shubhabrata, additional, Yu, Lan, additional, and Snitz, Beth E., additional

Published
2022
Full Text
View/download PDF

82. Health status and risk profiles for brain aging of rural-dwelling older adults : Data from the interdisciplinary baseline assessments in MIND-China

Author

Wang, Yongxiang, Han, Xiaolei, Zhang, Xianda, Zhang, Zhonglin, Cong, Lin, Tang, Shi, Hou, Tingting, Liu, Cuicui, Han, Xiaojuan, Zhang, Qinghua, Feng, Jianli, Yin, Ling, Song, Lin, Dong, Yi, Liu, Rui, Li, Yuanjing, Ngandu, Tiia, Kivipelto, Miia, Snyder, Heather, Carrillo, Maria, Persson, Jonas, Fratiglioni, Laura, Launer, Lenore J., Jia, Jianping, Du, Yifeng, Qiu, Chengxuan, Wang, Yongxiang, Han, Xiaolei, Zhang, Xianda, Zhang, Zhonglin, Cong, Lin, Tang, Shi, Hou, Tingting, Liu, Cuicui, Han, Xiaojuan, Zhang, Qinghua, Feng, Jianli, Yin, Ling, Song, Lin, Dong, Yi, Liu, Rui, Li, Yuanjing, Ngandu, Tiia, Kivipelto, Miia, Snyder, Heather, Carrillo, Maria, Persson, Jonas, Fratiglioni, Laura, Launer, Lenore J., Jia, Jianping, Du, Yifeng, and Qiu, Chengxuan

Abstract

Introduction: Multidomain intervention approaches have emerged as a potential strategy to reduce dementia risk. We sought to describe the baseline assessment approaches, health conditions, and risk profiles for brain aging of participants in the randomized controlled Multimodal INterventions to delay Dementia and disability in rural China (MIND-China). Methods: MIND-China engaged residents who were >= 60 years of age and living in rural communities in the western Shandong province. In March to September 2018, all participants underwent the core module assessments via face-to-face interviews, clinical examinations, neuropsychological testings, and laboratory tests. Specific modules of examination were performed for sub-samples, including brain magnetic resonance imaging scans, genetic and blood biochemical markers, actigraphy testing, cardiopulmonary coupling analysis for sleep quality and disturbances, audiometric testing, and optical coherence tomography examination. We performed descriptive analysis. Results: In total, 5765 participants (74.9% of all eligible residents) undertook the baseline assessments. The mean age was 70.9 years (standard deviation, 5.9), 57.2% were women, 40.6% were illiterate, and 88.3% were farmers. The overall prevalence of common chronic diseases was 67.2% for hypertension, 23.4% for dyslipidemia, 23.5% for heart disease, 14.4% for diabetes mellitus, and 5.4% for dementia. The prevalence rates of hypertension, diabetes mellitus, dyslipidemia, obesity, heart disease, depressive symptoms, and dementia were higher in women than in men (P < .05). Overall, 87.1% of the participants had at least two of the 15 chronic diseases (89.3% in women vs 84.2% in men, P < .001). Participants examined for the specific modules were younger, more likely to be women, and more educated than those not examined. Discussion: Comprehensive baseline assessments of participants in MIND-China provide extremely valuable data sources for interdisciplinary res

Published
2022
Full Text
View/download PDF

83. Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium.

Author

de Erausquin, Gabriel A, de Erausquin, Gabriel A, Snyder, Heather, Brugha, Traolach S, Seshadri, Sudha, Carrillo, Maria, Sagar, Rajesh, Huang, Yueqin, Newton, Charles, Tartaglia, Carmela, Teunissen, Charlotte, Håkanson, Krister, Akinyemi, Rufus, Prasad, Kameshwar, D'Avossa, Giovanni, Gonzalez-Aleman, Gabriela, Hosseini, Akram, Vavougios, George D, Sachdev, Perminder, Bankart, John, Mors, Niels Peter Ole, Lipton, Richard, Katz, Mindy, Fox, Peter T, Katshu, Mohammad Zia, Iyengar, M Sriram, Weinstein, Galit, Sohrabi, Hamid R, Jenkins, Rachel, Stein, Dan J, Hugon, Jacques, Mavreas, Venetsanos, Blangero, John, Cruchaga, Carlos, Krishna, Murali, Wadoo, Ovais, Becerra, Rodrigo, Zwir, Igor, Longstreth, William T, Kroenenberg, Golo, Edison, Paul, Mukaetova-Ladinska, Elizabeta, Staufenberg, Ekkehart, Figueredo-Aguiar, Mariana, Yécora, Agustín, Vaca, Fabiana, Zamponi, Hernan P, Re, Vincenzina Lo, Majid, Abdul, Sundarakumar, Jonas, Gonzalez, Hector M, Geerlings, Mirjam I, Skoog, Ingmar, Salmoiraghi, Alberto, Boneschi, Filippo Martinelli, Patel, Vibuthi N, Santos, Juan M, Arroyo, Guillermo Rivera, Moreno, Antonio Caballero, Felix, Pascal, Gallo, Carla, Arai, Hidenori, Yamada, Masahito, Iwatsubo, Takeshi, Sharma, Malveeka, Chakraborty, Nandini, Ferreccio, Catterina, Akena, Dickens, Brayne, Carol, Maestre, Gladys, Blangero, Sarah Williams, Brusco, Luis I, Siddarth, Prabha, Hughes, Timothy M, Zuñiga, Alfredo Ramírez, Kambeitz, Joseph, Laza, Agustin Ruiz, Allen, Norrina, Panos, Stella, Merrill, David, Ibáñez, Agustín, Tsuang, Debby, Valishvili, Nino, Shrestha, Srishti, Wang, Sophia, Padma, Vasantha, Anstey, Kaarin J, Ravindrdanath, Vijayalakshmi, Blennow, Kaj, Mullins, Paul, Łojek, Emilia, Pria, Anand, Mosley, Thomas H, Gowland, Penny, Girard, Timothy D, Bowtell, Richard, Vahidy, Farhaan S, de Erausquin, Gabriel A, de Erausquin, Gabriel A, Snyder, Heather, Brugha, Traolach S, Seshadri, Sudha, Carrillo, Maria, Sagar, Rajesh, Huang, Yueqin, Newton, Charles, Tartaglia, Carmela, Teunissen, Charlotte, Håkanson, Krister, Akinyemi, Rufus, Prasad, Kameshwar, D'Avossa, Giovanni, Gonzalez-Aleman, Gabriela, Hosseini, Akram, Vavougios, George D, Sachdev, Perminder, Bankart, John, Mors, Niels Peter Ole, Lipton, Richard, Katz, Mindy, Fox, Peter T, Katshu, Mohammad Zia, Iyengar, M Sriram, Weinstein, Galit, Sohrabi, Hamid R, Jenkins, Rachel, Stein, Dan J, Hugon, Jacques, Mavreas, Venetsanos, Blangero, John, Cruchaga, Carlos, Krishna, Murali, Wadoo, Ovais, Becerra, Rodrigo, Zwir, Igor, Longstreth, William T, Kroenenberg, Golo, Edison, Paul, Mukaetova-Ladinska, Elizabeta, Staufenberg, Ekkehart, Figueredo-Aguiar, Mariana, Yécora, Agustín, Vaca, Fabiana, Zamponi, Hernan P, Re, Vincenzina Lo, Majid, Abdul, Sundarakumar, Jonas, Gonzalez, Hector M, Geerlings, Mirjam I, Skoog, Ingmar, Salmoiraghi, Alberto, Boneschi, Filippo Martinelli, Patel, Vibuthi N, Santos, Juan M, Arroyo, Guillermo Rivera, Moreno, Antonio Caballero, Felix, Pascal, Gallo, Carla, Arai, Hidenori, Yamada, Masahito, Iwatsubo, Takeshi, Sharma, Malveeka, Chakraborty, Nandini, Ferreccio, Catterina, Akena, Dickens, Brayne, Carol, Maestre, Gladys, Blangero, Sarah Williams, Brusco, Luis I, Siddarth, Prabha, Hughes, Timothy M, Zuñiga, Alfredo Ramírez, Kambeitz, Joseph, Laza, Agustin Ruiz, Allen, Norrina, Panos, Stella, Merrill, David, Ibáñez, Agustín, Tsuang, Debby, Valishvili, Nino, Shrestha, Srishti, Wang, Sophia, Padma, Vasantha, Anstey, Kaarin J, Ravindrdanath, Vijayalakshmi, Blennow, Kaj, Mullins, Paul, Łojek, Emilia, Pria, Anand, Mosley, Thomas H, Gowland, Penny, Girard, Timothy D, Bowtell, Richard, and Vahidy, Farhaan S

Abstract

IntroductionCoronavirus disease 2019 (COVID-19) has caused >3.5 million deaths worldwide and affected >160 million people. At least twice as many have been infected but remained asymptomatic or minimally symptomatic. COVID-19 includes central nervous system manifestations mediated by inflammation and cerebrovascular, anoxic, and/or viral neurotoxicity mechanisms. More than one third of patients with COVID-19 develop neurologic problems during the acute phase of the illness, including loss of sense of smell or taste, seizures, and stroke. Damage or functional changes to the brain may result in chronic sequelae. The risk of incident cognitive and neuropsychiatric complications appears independent from the severity of the original pulmonary illness. It behooves the scientific and medical community to attempt to understand the molecular and/or systemic factors linking COVID-19 to neurologic illness, both short and long term.MethodsThis article describes what is known so far in terms of links among COVID-19, the brain, neurological symptoms, and Alzheimer's disease (AD) and related dementias. We focus on risk factors and possible molecular, inflammatory, and viral mechanisms underlying neurological injury. We also provide a comprehensive description of the Alzheimer's Association Consortium on Chronic Neuropsychiatric Sequelae of SARS-CoV-2 infection (CNS SC2) harmonized methodology to address these questions using a worldwide network of researchers and institutions.ResultsSuccessful harmonization of designs and methods was achieved through a consensus process initially fragmented by specific interest groups (epidemiology, clinical assessments, cognitive evaluation, biomarkers, and neuroimaging). Conclusions from subcommittees were presented to the whole group and discussed extensively. Presently data collection is ongoing at 19 sites in 12 countries representing Asia, Africa, the Americas, and Europe.DiscussionThe Alzheimer's Association Global Consortium harmoniz

Published
2022

84. Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium

Author

de Erausquin, Gabriel A., Snyder, Heather, Brugha, Traolach S., Seshadri, Sudha, Carrillo, Maria, Sagar, Rajesh, Huang, Yueqin, Newton, Charles, Tartaglia, Carmela, Teunissen, Charlotte, Hakanson, Krister, Akinyemi, Rufus, Prasad, Kameshwar, D'Avossa, Giovanni, Gonzalez-Aleman, Gabriela, Hosseini, Akram, Vavougios, George D., Sachdev, Perminder, Bankart, John, Mors, Niels Peter Ole, Lipton, Richard, Katz, Mindy, Fox, Peter T., Katshu, Mohammad Zia, Iyengar, M. Sriram, Weinstein, Galit, Sohrabi, Hamid R., Jenkins, Rachel, Stein, Dan J., Hugon, Jacques, Mavreas, Venetsanos, Blangero, John, Cruchaga, Carlos, Krishna, Murali, Wadoo, Ovais, Becerra, Rodrigo, Zwir, Igor, Longstreth, William T., Kroenenberg, Golo, Edison, Paul, Mukaetova-Ladinska, Elizabeta, Staufenberg, Ekkehart, Figueredo-Aguiar, Mariana, Yecora, Agustin, Vaca, Fabiana, Zamponi, Hernan P., Lo Re, Vincenzina, Majid, Abdul, Sundarakumar, Jonas, Gonzalez, Hector M., Geerlings, Mirjam, I, Skoog, Ingmar, Salmoiraghi, Alberto, Boneschi, Filippo Martinelli, Patel, Vibuthi N., Santos, Juan M., Rivera Arroyo, Guillermo, Caballero Moreno, Antonio, Felix, Pascal, Gallo, Carla, Arai, Hidenori, Yamada, Masahito, Iwatsubo, Takeshi, Sharma, Malveeka, Chakraborty, Nandini, Ferreccio, Catterina, Akena, Dickens, Brayne, Carol, Maestre, Gladys, Blangero, Sarah Williams, Brusco, Luis, I, Siddarth, Prabha, Hughes, Timothy M., Zuniga, Alfredo Ramirez, Kambeitz, Joseph, Laza, Agustin Ruiz, Allen, Norrina, Panos, Stella, Merrill, David, Ibanez, Agustin, Tsuang, Debby, Valishvili, Nino, Shrestha, Srishti, Wang, Sophia, Padma, Vasantha, Anstey, Kaarin J., Ravindrdanath, Vijayalakshmi, Blennow, Kaj, Mullins, Paul, Pria, Anand, Mosley, Thomas H., Gowland, Penny, Girard, Timothy D., Bowtell, Richard, Vahidy, Farhaan S., de Erausquin, Gabriel A., Snyder, Heather, Brugha, Traolach S., Seshadri, Sudha, Carrillo, Maria, Sagar, Rajesh, Huang, Yueqin, Newton, Charles, Tartaglia, Carmela, Teunissen, Charlotte, Hakanson, Krister, Akinyemi, Rufus, Prasad, Kameshwar, D'Avossa, Giovanni, Gonzalez-Aleman, Gabriela, Hosseini, Akram, Vavougios, George D., Sachdev, Perminder, Bankart, John, Mors, Niels Peter Ole, Lipton, Richard, Katz, Mindy, Fox, Peter T., Katshu, Mohammad Zia, Iyengar, M. Sriram, Weinstein, Galit, Sohrabi, Hamid R., Jenkins, Rachel, Stein, Dan J., Hugon, Jacques, Mavreas, Venetsanos, Blangero, John, Cruchaga, Carlos, Krishna, Murali, Wadoo, Ovais, Becerra, Rodrigo, Zwir, Igor, Longstreth, William T., Kroenenberg, Golo, Edison, Paul, Mukaetova-Ladinska, Elizabeta, Staufenberg, Ekkehart, Figueredo-Aguiar, Mariana, Yecora, Agustin, Vaca, Fabiana, Zamponi, Hernan P., Lo Re, Vincenzina, Majid, Abdul, Sundarakumar, Jonas, Gonzalez, Hector M., Geerlings, Mirjam, I, Skoog, Ingmar, Salmoiraghi, Alberto, Boneschi, Filippo Martinelli, Patel, Vibuthi N., Santos, Juan M., Rivera Arroyo, Guillermo, Caballero Moreno, Antonio, Felix, Pascal, Gallo, Carla, Arai, Hidenori, Yamada, Masahito, Iwatsubo, Takeshi, Sharma, Malveeka, Chakraborty, Nandini, Ferreccio, Catterina, Akena, Dickens, Brayne, Carol, Maestre, Gladys, Blangero, Sarah Williams, Brusco, Luis, I, Siddarth, Prabha, Hughes, Timothy M., Zuniga, Alfredo Ramirez, Kambeitz, Joseph, Laza, Agustin Ruiz, Allen, Norrina, Panos, Stella, Merrill, David, Ibanez, Agustin, Tsuang, Debby, Valishvili, Nino, Shrestha, Srishti, Wang, Sophia, Padma, Vasantha, Anstey, Kaarin J., Ravindrdanath, Vijayalakshmi, Blennow, Kaj, Mullins, Paul, Pria, Anand, Mosley, Thomas H., Gowland, Penny, Girard, Timothy D., Bowtell, Richard, and Vahidy, Farhaan S.

Abstract

Introduction Coronavirus disease 2019 (COVID-19) has caused >3.5 million deaths worldwide and affected >160 million people. At least twice as many have been infected but remained asymptomatic or minimally symptomatic. COVID-19 includes central nervous system manifestations mediated by inflammation and cerebrovascular, anoxic, and/or viral neurotoxicity mechanisms. More than one third of patients with COVID-19 develop neurologic problems during the acute phase of the illness, including loss of sense of smell or taste, seizures, and stroke. Damage or functional changes to the brain may result in chronic sequelae. The risk of incident cognitive and neuropsychiatric complications appears independent from the severity of the original pulmonary illness. It behooves the scientific and medical community to attempt to understand the molecular and/or systemic factors linking COVID-19 to neurologic illness, both short and long term. Methods This article describes what is known so far in terms of links among COVID-19, the brain, neurological symptoms, and Alzheimer's disease (AD) and related dementias. We focus on risk factors and possible molecular, inflammatory, and viral mechanisms underlying neurological injury. We also provide a comprehensive description of the Alzheimer's Association Consortium on Chronic Neuropsychiatric Sequelae of SARS-CoV-2 infection (CNS SC2) harmonized methodology to address these questions using a worldwide network of researchers and institutions. Results Successful harmonization of designs and methods was achieved through a consensus process initially fragmented by specific interest groups (epidemiology, clinical assessments, cognitive evaluation, biomarkers, and neuroimaging). Conclusions from subcommittees were presented to the whole group and discussed extensively. Presently data collection is ongoing at 19 sites in 12 countries representing Asia, Africa, the Americas, and Europe. Discussion The Alzheimer's Association Global Consortium harmoni

Published
2022

85. Nutrition state of science and dementia prevention:recommendations of the Nutrition for Dementia Prevention Working Group

Author

Yassine, Hussein N., Samieri, Cécilia, Livingston, Gill, Glass, Kimberly, Wagner, Maude, Tangney, Christy, Plassman, Brenda L., Ikram, M. Arfan, Voigt, Robin M., Gu, Yian, O'Bryant, Sid, Minihane, Anne Marie, Craft, Suzanne, Fink, Howard A., Judd, Suzanne, Andrieu, Sandrine, Bowman, Gene L., Richard, Edo, Albensi, Benedict, Meyers, Emily, Khosravian, Serly, Solis, Michele, Carrillo, Maria, Snyder, Heather, Grodstein, Francine, Scarmeas, Nikolaos, Schneider, Lon S., Yassine, Hussein N., Samieri, Cécilia, Livingston, Gill, Glass, Kimberly, Wagner, Maude, Tangney, Christy, Plassman, Brenda L., Ikram, M. Arfan, Voigt, Robin M., Gu, Yian, O'Bryant, Sid, Minihane, Anne Marie, Craft, Suzanne, Fink, Howard A., Judd, Suzanne, Andrieu, Sandrine, Bowman, Gene L., Richard, Edo, Albensi, Benedict, Meyers, Emily, Khosravian, Serly, Solis, Michele, Carrillo, Maria, Snyder, Heather, Grodstein, Francine, Scarmeas, Nikolaos, and Schneider, Lon S.

Abstract

Observational studies suggest that nutritional factors have a potential cognitive benefit. However, systematic reviews of randomised trials of dietary and nutritional supplements have reported largely null effects on cognitive outcomes and have highlighted study inconsistencies and other limitations. In this Personal View, the Nutrition for Dementia Prevention Working Group presents what we consider to be limitations in the existing nutrition clinical trials for dementia prevention. On the basis of this evidence, we propose recommendations for incorporating dietary patterns and the use of genetic, and nutrition assessment tools, biomarkers, and novel clinical trial designs to guide future trial developments. Nutrition-based research has unique challenges that could require testing both more personalised interventions in targeted risk subgroups, identified by nutritional and other biomarkers, and large-scale and pragmatic study designs for more generalisable public health interventions across diverse populations.

Published
2022

86. Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium

Author

Cardiovasculaire Epi Team 7a, Brain, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, de Erausquin, Gabriel A, Snyder, Heather, Brugha, Traolach S, Seshadri, Sudha, Carrillo, Maria, Sagar, Rajesh, Huang, Yueqin, Newton, Charles, Tartaglia, Carmela, Teunissen, Charlotte, Håkanson, Krister, Akinyemi, Rufus, Prasad, Kameshwar, D'Avossa, Giovanni, Gonzalez-Aleman, Gabriela, Hosseini, Akram, Vavougios, George D, Sachdev, Perminder, Bankart, John, Mors, Niels Peter Ole, Lipton, Richard, Katz, Mindy, Fox, Peter T, Katshu, Mohammad Zia, Iyengar, M Sriram, Weinstein, Galit, Sohrabi, Hamid R, Jenkins, Rachel, Stein, Dan J, Hugon, Jacques, Mavreas, Venetsanos, Blangero, John, Cruchaga, Carlos, Krishna, Murali, Wadoo, Ovais, Becerra, Rodrigo, Zwir, Igor, Longstreth, William T, Kroenenberg, Golo, Edison, Paul, Mukaetova-Ladinska, Elizabeta, Staufenberg, Ekkehart, Figueredo-Aguiar, Mariana, Yécora, Agustín, Vaca, Fabiana, Zamponi, Hernan P, Re, Vincenzina Lo, Majid, Abdul, Sundarakumar, Jonas, Gonzalez, Hector M, Geerlings, Mirjam I, Skoog, Ingmar, Salmoiraghi, Alberto, Boneschi, Filippo Martinelli, Patel, Vibuthi N, Santos, Juan M, Arroyo, Guillermo Rivera, Moreno, Antonio Caballero, Felix, Pascal, Gallo, Carla, Arai, Hidenori, Yamada, Masahito, Iwatsubo, Takeshi, Sharma, Malveeka, Chakraborty, Nandini, Ferreccio, Catterina, Akena, Dickens, Brayne, Carol, Maestre, Gladys, Blangero, Sarah Williams, Brusco, Luis I, Siddarth, Prabha, Hughes, Timothy M, Zuñiga, Alfredo Ramírez, Kambeitz, Joseph, Laza, Agustin Ruiz, Allen, Norrina, Panos, Stella, Merrill, David, Ibáñez, Agustín, Tsuang, Debby, Valishvili, Nino, Shrestha, Srishti, Wang, Sophia, Padma, Vasantha, Anstey, Kaarin J, Ravindrdanath, Vijayalakshmi, Blennow, Kaj, Mullins, Paul, Łojek, Emilia, Pria, Anand, Mosley, Thomas H, Gowland, Penny, Girard, Timothy D, Bowtell, Richard, Vahidy, Farhaan S, Cardiovasculaire Epi Team 7a, Brain, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, de Erausquin, Gabriel A, Snyder, Heather, Brugha, Traolach S, Seshadri, Sudha, Carrillo, Maria, Sagar, Rajesh, Huang, Yueqin, Newton, Charles, Tartaglia, Carmela, Teunissen, Charlotte, Håkanson, Krister, Akinyemi, Rufus, Prasad, Kameshwar, D'Avossa, Giovanni, Gonzalez-Aleman, Gabriela, Hosseini, Akram, Vavougios, George D, Sachdev, Perminder, Bankart, John, Mors, Niels Peter Ole, Lipton, Richard, Katz, Mindy, Fox, Peter T, Katshu, Mohammad Zia, Iyengar, M Sriram, Weinstein, Galit, Sohrabi, Hamid R, Jenkins, Rachel, Stein, Dan J, Hugon, Jacques, Mavreas, Venetsanos, Blangero, John, Cruchaga, Carlos, Krishna, Murali, Wadoo, Ovais, Becerra, Rodrigo, Zwir, Igor, Longstreth, William T, Kroenenberg, Golo, Edison, Paul, Mukaetova-Ladinska, Elizabeta, Staufenberg, Ekkehart, Figueredo-Aguiar, Mariana, Yécora, Agustín, Vaca, Fabiana, Zamponi, Hernan P, Re, Vincenzina Lo, Majid, Abdul, Sundarakumar, Jonas, Gonzalez, Hector M, Geerlings, Mirjam I, Skoog, Ingmar, Salmoiraghi, Alberto, Boneschi, Filippo Martinelli, Patel, Vibuthi N, Santos, Juan M, Arroyo, Guillermo Rivera, Moreno, Antonio Caballero, Felix, Pascal, Gallo, Carla, Arai, Hidenori, Yamada, Masahito, Iwatsubo, Takeshi, Sharma, Malveeka, Chakraborty, Nandini, Ferreccio, Catterina, Akena, Dickens, Brayne, Carol, Maestre, Gladys, Blangero, Sarah Williams, Brusco, Luis I, Siddarth, Prabha, Hughes, Timothy M, Zuñiga, Alfredo Ramírez, Kambeitz, Joseph, Laza, Agustin Ruiz, Allen, Norrina, Panos, Stella, Merrill, David, Ibáñez, Agustín, Tsuang, Debby, Valishvili, Nino, Shrestha, Srishti, Wang, Sophia, Padma, Vasantha, Anstey, Kaarin J, Ravindrdanath, Vijayalakshmi, Blennow, Kaj, Mullins, Paul, Łojek, Emilia, Pria, Anand, Mosley, Thomas H, Gowland, Penny, Girard, Timothy D, Bowtell, Richard, and Vahidy, Farhaan S

Published
2022

87. Health status and risk profiles for brain aging of rural‐dwelling older adults: Data from the interdisciplinary baseline assessments in MIND‐China

Author

Wang, Yongxiang, primary, Han, Xiaolei, additional, Zhang, Xianda, additional, Zhang, Zhonglin, additional, Cong, Lin, additional, Tang, Shi, additional, Hou, Tingting, additional, Liu, Cuicui, additional, Han, Xiaojuan, additional, Zhang, Qinghua, additional, Feng, Jianli, additional, Yin, Ling, additional, Song, Lin, additional, Dong, Yi, additional, Liu, Rui, additional, Li, Yuanjing, additional, Ngandu, Tiia, additional, Kivipelto, Miia, additional, Snyder, Heather, additional, Carrillo, Maria, additional, Persson, Jonas, additional, Fratiglioni, Laura, additional, Launer, Lenore J, additional, Jia, Jianping, additional, Du, Yifeng, additional, and Qiu, Chengxuan, additional

Published
2022
Full Text
View/download PDF

88. Chronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium

Author

de Erausquin, Gabriel A., primary, Snyder, Heather, additional, Brugha, Traolach S., additional, Seshadri, Sudha, additional, Carrillo, Maria, additional, Sagar, Rajesh, additional, Huang, Yueqin, additional, Newton, Charles, additional, Tartaglia, Carmela, additional, Teunissen, Charlotte, additional, Håkanson, Krister, additional, Akinyemi, Rufus, additional, Prasad, Kameshwar, additional, D'Avossa, Giovanni, additional, Gonzalez‐Aleman, Gabriela, additional, Hosseini, Akram, additional, Vavougios, George D., additional, Sachdev, Perminder, additional, Bankart, John, additional, Mors, Niels Peter Ole, additional, Lipton, Richard, additional, Katz, Mindy, additional, Fox, Peter T., additional, Katshu, Mohammad Zia, additional, Iyengar, M. Sriram, additional, Weinstein, Galit, additional, Sohrabi, Hamid R., additional, Jenkins, Rachel, additional, Stein, Dan J., additional, Hugon, Jacques, additional, Mavreas, Venetsanos, additional, Blangero, John, additional, Cruchaga, Carlos, additional, Krishna, Murali, additional, Wadoo, Ovais, additional, Becerra, Rodrigo, additional, Zwir, Igor, additional, Longstreth, William T., additional, Kroenenberg, Golo, additional, Edison, Paul, additional, Mukaetova‐Ladinska, Elizabeta, additional, Staufenberg, Ekkehart, additional, Figueredo‐Aguiar, Mariana, additional, Yécora, Agustín, additional, Vaca, Fabiana, additional, Zamponi, Hernan P., additional, Re, Vincenzina Lo, additional, Majid, Abdul, additional, Sundarakumar, Jonas, additional, Gonzalez, Hector M., additional, Geerlings, Mirjam I., additional, Skoog, Ingmar, additional, Salmoiraghi, Alberto, additional, Boneschi, Filippo Martinelli, additional, Patel, Vibuthi N., additional, Santos, Juan M., additional, Arroyo, Guillermo Rivera, additional, Moreno, Antonio Caballero, additional, Felix, Pascal, additional, Gallo, Carla, additional, Arai, Hidenori, additional, Yamada, Masahito, additional, Iwatsubo, Takeshi, additional, Sharma, Malveeka, additional, Chakraborty, Nandini, additional, Ferreccio, Catterina, additional, Akena, Dickens, additional, Brayne, Carol, additional, Maestre, Gladys, additional, Blangero, Sarah Williams, additional, Brusco, Luis I., additional, Siddarth, Prabha, additional, Hughes, Timothy M., additional, Zuñiga, Alfredo Ramírez, additional, Kambeitz, Joseph, additional, Laza, Agustin Ruiz, additional, Allen, Norrina, additional, Panos, Stella, additional, Merrill, David, additional, Ibáñez, Agustín, additional, Tsuang, Debby, additional, Valishvili, Nino, additional, Shrestha, Srishti, additional, Wang, Sophia, additional, Padma, Vasantha, additional, Anstey, Kaarin J., additional, Ravindrdanath, Vijayalakshmi, additional, Blennow, Kaj, additional, Mullins, Paul, additional, Łojek, Emilia, additional, Pria, Anand, additional, Mosley, Thomas H., additional, Gowland, Penny, additional, Girard, Timothy D., additional, Bowtell, Richard, additional, and Vahidy, Farhaan S., additional

Published
2022
Full Text
View/download PDF

89. Methodological challenges across WW‐FINGERS Studies: Impact of COVID‐19 pandemic on statistical design and analysis plans for multidomain RCTs

Author

Espeland, Mark A, primary, Roehr, Susanne, additional, Arai, Hidenori, additional, Mangialasche, Francesca, additional, Peltonen, Markku, additional, Raman, Rema, additional, Riedel‐Heller, Steffi G, additional, Snyder, Heather M, additional, Carrillo, Maria C, additional, Ngandu, Tiia, additional, and Kivipelto, Miia, additional

Published
2021
Full Text
View/download PDF

90. Tools for harmonization of data in World‐Wide FINGERS

Author

Talton, Jennifer W, primary, Fernandez, Shane, additional, Garcia, Katelyn R, additional, Crivelli, Lucia, additional, Snyder, Heather M, additional, Lovato, Laura, additional, Martins, Ralph N, additional, Kivipelto, Miia, additional, Mangialasche, Francesca, additional, Pérez, Kristal Morales, additional, and Espeland, Mark A, additional

Published
2021
Full Text
View/download PDF

91. The PRagmatic EValuation of evENTs And Benefits of Lipid‐lowering in oldEr adults (PREVENTABLE) trial: Study design and procedures for cognitive assessment and adjudication

Author

Sachs, Bonnie C., primary, Rapp, Stephen R., additional, Kistler, Christine E, additional, Musi, Nicolas, additional, Supiano, Mark A., additional, Pajewski, Nicholas M., additional, Callahan, Kathryn E., additional, Alexander, Karen P., additional, Shah, Raj C, additional, Snyder, Heather M., additional, Carrillo, Maria C., additional, Espinoza, Sara, additional, and Williamson, Jeff D., additional

Published
2021
Full Text
View/download PDF

92. Evaluation of Medications Used for Hospitalized Patients With Sleep Disturbances: A Frequency Analysis and Literature Review.

Author

White, Brittany, Snyder, Heather S., and Patel, Megan Van Berkel

Subjects
*BENZODIAZEPINES, *RETROSPECTIVE studies, *SLEEP disorders, *MELATONIN, *HOSPITAL care, *DESCRIPTIVE statistics, *MEDICAL prescriptions, *MEDLINE, *TRANQUILIZING drugs
Abstract

Purpose: Poor sleep during hospitalization is common and implicated in worse patient outcomes. Despite implementation of non-pharmacologic techniques, medications are still frequently required. The study objective is to assess the frequency of new medications administered for sleep in hospitalized patients and to review literature evaluating these drug therapies in the inpatient setting. Methods: This retrospective study included adult inpatients if they received a new medication for sleep during a 5-day period. Patients were excluded if the medication was continued from home or if sleep was not the documented indication. For the literature review, a MEDLINE search was conducted to identify studies pertaining to pharmacotherapy for sleep in hospitalized patients. Results: Of 1,968 patient-days reviewed, a medication for sleep was given for 166 patient-days (8.4%) in 78 patients. Melatonin was most commonly received (70.5%), followed by benzodiazepines (9.6%). A review of antihistamines, benzodiazepines, melatonin, quetiapine, trazodone, and Z-drugs (non-benzodiazepine hypnotics) was conducted and 23 studies were included. Conclusions: Despite widespread use of pharmacotherapy for sleep, there is a paucity of data evaluating use in the inpatient setting. Although there is significant heterogeneity among studies, melatonin has the strongest evidence for use and is an attractive option given its lack of adverse reactions and drug interactions. Benzodiazepines and Z-drugs were also frequently utilized; however, their reduced clearance in the elderly and potential for compounded sedative effects should be weighed heavily against potential sleep benefits. Antipsychotic agents cannot be recommended for routine use due to limited data and the potential for significant adverse effects. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

95. Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID‐19 pandemic

Author

Meyers, Emily A., primary, Amouyel, Philippe, additional, Bovenkamp, Diane E., additional, Carrillo, Maria C., additional, De Buchy, Geraldine Drexel, additional, Dumont, Magali, additional, Fillit, Howard, additional, Friedman, Lauren, additional, Henderson‐Begg, Gregor, additional, Hort, Jakub, additional, Murtishaw, Andrew, additional, Oakley, Richard, additional, Panchal, Maï, additional, Rossi, Sharyn L., additional, Sancho, Rosa M., additional, Thienpont, Linda, additional, Weidner, Wendy, additional, and Snyder, Heather M., additional

Published
2021
Full Text
View/download PDF

96. Current directions in tau research: Highlights from Tau 2020

Author

Sexton, Claire, primary, Snyder, Heather, additional, Beher, Dirk, additional, Boxer, Adam L., additional, Brannelly, Pat, additional, Brion, Jean‐Pierre, additional, Buée, Luc, additional, Cacace, Angela M., additional, Chételat, Gaël, additional, Citron, Martin, additional, DeVos, Sarah L., additional, Diaz, Kristophe, additional, Feldman, Howard H., additional, Frost, Bess, additional, Goate, Alison M., additional, Gold, Michael, additional, Hyman, Bradley, additional, Johnson, Keith, additional, Karch, Celeste M., additional, Kerwin, Diana R., additional, Koroshetz, Walter J., additional, Litvan, Irene, additional, Morris, Huw R., additional, Mummery, Catherine J., additional, Mutamba, James, additional, Patterson, Marc C., additional, Quiroz, Yakeel T., additional, Rabinovici, Gil D., additional, Rommel, Amy, additional, Shulman, Melanie B., additional, Toledo‐Sherman, Leticia M., additional, Weninger, Stacie, additional, Wildsmith, Kristin R., additional, Worley, Susan L., additional, and Carrillo, Maria C., additional

Published
2021
Full Text
View/download PDF

97. Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina

Author

Zamponi, Hernan P., Juarez-Aguayso, Leonardo, Kukoc, Gabriela, Domínguez, María Eugenia, Pini, Belén, Padilla, Eduardo G., Calvó, María, Molina-Rangeon, Silvia Beatriz, Guerrero, Gonzalo, Figueredo-Aguiar, Mariana, Fumagalli, Emiliano, Yécora, Agustín, Brugha, Traolach S., Seshadri, Sudha, Snyder, Heather M., Erausquin, Gabriel A. de, and Gonzalez-Aleman, Gabriela

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, SARS-CoV-2, Health Policy, ADULTOS MAYORES, ANOSMIA PERSISTENTE, COVID-19, Neurology (clinical), Geriatrics and Gerontology, DETERIORO COGNITIVO, DISFUNCION OLFATORIA
Abstract

Fil: Zamponi, Hernan P. Ministerio de Salud de Jujuy; Argentina Fil: Juarez-Aguayso, Leonardo. Ministerio de Salud de Jujuy; Argentina Fil: Kukoc, Gabriela. Ministerio de Salud de Jujuy; Argentina Fil: Domínguez, María Eugenia. Ministerio de Salud de Jujuy; Argentina Fil: Pini, Belén. Ministerio de Salud de Jujuy; Argentina Fil: Padilla, Eduardo G. Fundación de lucha contra los trastornos neurológicos y psiquiátricos en minorías; Argentina Fil: Calvó, María. Fundación de lucha contra los trastornos neurológicos y psiquiátricos en minorías; Argentina Fil: Molina-Rangeon, Silvia Beatriz. Fundación de lucha contra los trastornos neurológicos y psiquiátricos en minorías; Argentina Fil: Guerrero, Gonzalo. Fundación de lucha contra los trastornos neurológicos y psiquiátricos en minorías; Argentina Fil: Figueredo-Aguiar, Mariana. Fundación de lucha contra los trastornos neurológicos y psiquiátricos en minorías; Argentina Fil: Fumagalli, Emiliano. Universidad Nacional de Jujuy; Argentina Fil: Yécora, Agustín. Ministerio de Salud de Jujuy; Argentina Fil: Brugha, Traolach S. University of Leicester; Reino Unido Fil: Seshadri, Sudha. University of Texas Health Science Center at San Antonio; Estados Unidos Fil: Seshadri, Sudha. Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases; Estados Unidos Fil: Snyder, Heather M. Alzheimer’s Association; Argentina Fil: Erausquin, Gabriel A. de. Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases; Estados Unidos Fil: Erausquin, Gabriel A. de. University of Texas Health Science Center at San Antonio; Estados Unidos Fil: Gonzalez-Aleman, Gabriela. Pontificia Universidad Católica Argentina; Argentina Abstract: Background: COVID-19 has affected more than 150 million people. The causal coronavirus, SARS-CoV-2 has infected twice as many individuals who have remained asymptomatic. COVID-19 includes central nervous system (CNS) manifestations and may result in chronic neuropsychiatric sequelae. Risk factors for COVID-19 sequelae overlap with those for Alzheimer’s disease (AD), particularly older age and ApoE4 status. The Alzheimer’s Association Consortium on Chronic Neuropsychiatric Sequelae of SARS-CoV-2 infection (CNS SC2) established harmonized definitions, ascertainment and assessment methodologies to evaluate and longitudinally follow up cohorts of older adults with variable exposure to COVID-19. We present preliminary data from CNS SC2 in a prospective cohort of 234 older adult Amerindians from Argentina. Method: Participants are ≥ 60 years recruited from the health registry of the Province of Jujuy containing all SARS-CoV-2 testing data (regardless of clinical status and of the result of the testing). We randomly invite older adults stratified by testing status regardless of symptom severity, a minimum of 3 months after clinical recovery (maximum 6 months); refusal to participate is

Published
2021

99. Alzheimer’s Association International Cohort Study of Chronic Neuropsychiatric Sequeale of SARS‐CoV‐2 (CNS‐SARS‐CoV‐2)

Author

de Erausquin, Gabriel A., Brusco, Ignacio, Zamponi, Hernan, Sachdev, Perminder S., Rivera Arroyo, Guillermo, Santos, Juan Matias, Huang, Yueqin, Caballero, Antonio, Mors, Niels Ole, Brugha, Terry, Mukaetova‐Ladinska, Elizabeta, Kronenberg, Golo D., Katshu, Mohammad Zia, Staufenberg, Ekkehart, Mavreas, Venos, Sagar, Rajesh, Padma, Vasantha, Ravindranath, Vijayalakshmi, Prasad, Kameshwar, Barbui, Corrado, Ostuzzi, Giovanni, Nienhuis, Fokko J., Ikram, M. Arfan, Gallo, Carla, Cutipé Cardenas, Yuri L., Paholpak, Suchat, Ganguli, Mary, Collins, Pamela Y., Seshadri, Sudha, D'Avossa, Giovanni, Salmoiraghi, Alberto, Carrillo, Maria C., Snyder, Heather M., and Dua, Tarun

Subjects
Poster Presentations, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Clinical Manifestations, Clinical Neurology, Geriatrics and Gerontology
Abstract

Background The pandemic of SARS‐CoV‐2 is focusing all energies on the impact on survival of affected individuals, treatment and prevention, but increasingly attention is focusing on its enduring consequences. We established a global consortium to study a longitudinal representative cohort of individuals, to characterize neurological and neuropsychiatric sequalae from direct viral, immune‐, vascular‐ or accelerated neurodegenerative injury to the central nervous system (CNS). Method We propose to characterize the neurobehavioral phenomenology associated with SARS‐CoV‐2 in a large, multinational, longitudinal cohort of post COVID‐19 infection patients following three sampling strategies: 1) Opportunity sample of patients discharged after hospital admission for COVID‐19 related symptoms. 2) A stratified random sample from COVID‐19 testing registries (including asymptomatic and negative participants). 3) Ascertaining COVID‐19 exposure (antibody) status in ongoing longitudinal, community‐based cohort studies that are already collecting biosamples, cognitive, behavioral and neuroimaging data. We will obtain core data within 6 months of discharge or testing. Core characterization will include interviews with the Schedules of Clinical Assessment in Neuropsychiatry (SCAN), neurological exams, emotional reactivity scales and a neurocognitive assessment. Wherever feasible, we will also collect neuroimaging, biosamples and genetic data. Longitudinal follow up will be conducted at 9 and 18 months of the initial evaluation. An mHealth keeping‐in‐touch process will be set up to minimize attrition rates. The population cohorts provide a large, unbiased, normative and validation sample, albeit with more heterogenous outcome ascertainment. They also permit examination of pre‐ and post‐COVID trends in symptoms and biomarkers. Since some ethnic groups, as well as in individuals with blood type A, are at higher risk of COVID‐19 infection and death, a role of genetics in determining susceptibility to infection and poor outcomes seems well supported. We will collect genome‐wide genotypes from our cohort individuals to address the role of ancestry and genetic variation on susceptibility to neuropsychiatric sequelae. High rates of mutation in COVID‐19 strongly suggest that viral infectivity, including neurotropism, may not be uniform across countries affected by the pandemic. Results Pending. Conclusion Our consortium is in a unique position to address the interaction between genetics (including ancestral DNA), and viral strain variation on CNS sequelae of SARS‐CoV‐2.

Published
2020
Full Text
View/download PDF

100. Retinal imaging in Alzheimer's and neurodegenerative diseases

Author

Snyder, Peter J., Alber, Jessica, Alt, Clemens, Bain, Lisa J., Bouma, Brett E., Bouwman, Femke H., Cabrera DeBuc, Delia, Campbell, Melanie C.W., Carrillo, Maria C., Chew, Emily Y., Cordeiro, M. Francesca, Dueñas, Michael R., Fernández, Brian M., Koronyo‐Hamaoui, Maya, La Morgia, Chiara, Carare, Roxana-Octavia, Sadda, Srinivas R., van Wijngaarden, Peter, and Snyder, Heather M.

Abstract

In the last 20 years, research focused on developing retinal imaging as a source of potential biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased significantly. The Alzheimer's Association and the Alzheimer's & Dementia: Diagnosis, Assessment, Disease Monitoring editorial team (companion journal to Alzheimer's & Dementia) convened an interdisciplinary discussion in 2019 to identify a path to expedite the development of retinal biomarkers capable of identifying biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results